BRPI0009299A - formas de administração farmacêuticas mecanicamente estáveis para administração por via oral, e, processo para produzir formas de administração farmacêuticas mecanicamente estáveis. - Google Patents

formas de administração farmacêuticas mecanicamente estáveis para administração por via oral, e, processo para produzir formas de administração farmacêuticas mecanicamente estáveis.

Info

Publication number
BRPI0009299A
BRPI0009299A BRPI0009299A BRPI0009299A BRPI0009299A BR PI0009299 A BRPI0009299 A BR PI0009299A BR PI0009299 A BRPI0009299 A BR PI0009299A BR PI0009299 A BRPI0009299 A BR PI0009299A BR PI0009299 A BRPI0009299 A BR PI0009299A
Authority
BR
Brazil
Prior art keywords
mechanically stable
stable pharmaceutical
administration forms
pharmaceutical administration
forms
Prior art date
Application number
BRPI0009299A
Other languages
English (en)
Inventor
Joerg Rosenberg
Gunther Berndl
Bernd Liepold
Joerg Breitenbach
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of BRPI0009299A publication Critical patent/BRPI0009299A/pt
Publication of BRPI0009299B1 publication Critical patent/BRPI0009299B1/pt
Publication of BRPI0009299B8 publication Critical patent/BRPI0009299B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Abstract

"formas de administração farmacêutica mecanicamente estável para administração oral, e, processo para produzir formas de administração farmacêutica mecanicamente estável". a invenção diz respeito à formas de formas de administração farmacêutica mecanicamente estáveis para a administração peroral, que além de um ou mais ingredientes ativos e pelo menos um auxiliar formador de matriz termoplasticamente moldável, contêm mais do que 10 e até 40 % em peso de uma substância ativa de superfície que tenha um hlb entre 2 e 18 e seja líquida a 20<198>c ou tenha um ponto de gotejamento entre 20 e 50<198>c.
BRPI0009299-1 1999-03-25 2000-03-17 formas de administração farmacêuticas mecanicamente estáveis para administração por via oral, e, processo para produzir formas de administração farmacêuticas mecanicamente estáveis. BRPI0009299B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19913692A DE19913692A1 (de) 1999-03-25 1999-03-25 Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
PCT/EP2000/002381 WO2000057854A2 (de) 1999-03-25 2000-03-17 Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen

Publications (3)

Publication Number Publication Date
BRPI0009299A true BRPI0009299A (pt) 2001-12-18
BRPI0009299B1 BRPI0009299B1 (pt) 2011-05-17
BRPI0009299B8 BRPI0009299B8 (pt) 2021-07-06

Family

ID=7902460

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0009299-1 BRPI0009299B8 (pt) 1999-03-25 2000-03-17 formas de administração farmacêuticas mecanicamente estáveis para administração por via oral, e, processo para produzir formas de administração farmacêuticas mecanicamente estáveis.

Country Status (9)

Country Link
US (1) US6599528B1 (pt)
EP (1) EP1162953B1 (pt)
JP (1) JP2002540139A (pt)
AT (1) ATE260647T1 (pt)
BR (1) BRPI0009299B8 (pt)
CA (1) CA2368138C (pt)
DE (2) DE19913692A1 (pt)
ES (1) ES2216873T3 (pt)
WO (1) WO2000057854A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19929361A1 (de) * 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
JP4997683B2 (ja) * 2000-09-25 2012-08-08 日本新薬株式会社 医薬固体分散体の製法
JP2005529059A (ja) * 2001-09-28 2005-09-29 マクニール−ピーピーシー・インコーポレイテッド 改質した放出用の投薬形態
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
JPWO2005065715A1 (ja) * 2003-12-25 2007-07-26 武田薬品工業株式会社 造粒性改善方法
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
PL2200588T3 (pl) 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
US8795634B2 (en) * 2008-09-12 2014-08-05 Critical Pharmaceuticals Limited Absorption of therapeutic agents across mucosal membranes or the skin
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
DK2455376T3 (en) 2009-06-11 2015-03-02 Abbvie Bahamas Ltd Heterocyclic compounds as inhibitors of hepatitis C virus (HCV)
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
AU2010336518B2 (en) 2009-12-22 2014-03-06 Abbvie Inc. ABT-263 capsule
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
CA2811805A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
RU2593231C2 (ru) 2010-11-23 2016-08-10 ЭббВи Айэленд Анлимитед Компани Способы лечения с использованием селективных ингибиторов bcl-2
CN107266435A (zh) 2010-11-23 2017-10-20 Abbvie 公司 细胞凋亡诱导剂的盐和晶形
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2714683A4 (en) 2011-05-27 2014-11-05 Hetero Research Foundation RITONAVIR AMORPH CO-PRECIPITATION
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
JP6301339B2 (ja) 2012-09-27 2018-03-28 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 少なくとも１種の水溶性ビタミンｅ誘導体および少なくとも１種の親水性ポリマーを含む、保存において安定な無塵の均質な粒子製剤
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
CN104661652B (zh) 2012-09-27 2018-08-28 巴斯夫欧洲公司 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US10034865B2 (en) 2015-09-10 2018-07-31 Kashiv Pharma, Llc Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
US20230295183A1 (en) 2020-02-24 2023-09-21 Newave Pharmaceutical Inc. Hot melt extruded solid dispersions containing a bcl2 inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3124983A1 (de) * 1981-06-25 1983-01-20 Meditest Inst Fuer Medizinisch Arzneiformen zur oralen verabreichung
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
ES2040697T3 (es) 1986-12-18 1993-11-01 Kurt H. Prof. Dr. Bauer Concentrado de nifedipina estabilizado frente a la influencia de la luz, y procedimiento para su preparacion.
DE4200821A1 (de) 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
ATE317397T1 (de) * 1993-11-17 2006-02-15 Athena Neurosciences Inc Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
DE19629753A1 (de) * 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
FR2756736B1 (fr) * 1996-12-05 1999-03-05 Sanofi Sa Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline
FR2764800B1 (fr) * 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne

Also Published As

Publication number Publication date
BRPI0009299B8 (pt) 2021-07-06
CA2368138C (en) 2006-08-22
JP2002540139A (ja) 2002-11-26
DE50005515D1 (de) 2004-04-08
CA2368138A1 (en) 2000-10-05
WO2000057854A3 (de) 2001-03-15
EP1162953A2 (de) 2001-12-19
US6599528B1 (en) 2003-07-29
DE19913692A1 (de) 2000-09-28
EP1162953B1 (de) 2004-03-03
WO2000057854A2 (de) 2000-10-05
ATE260647T1 (de) 2004-03-15
BRPI0009299B1 (pt) 2011-05-17
ES2216873T3 (es) 2004-11-01

Similar Documents

Publication Publication Date Title
BRPI0009299B1 (pt) formas de administração farmacêuticas mecanicamente estáveis para administração por via oral, e, processo para produzir formas de administração farmacêuticas mecanicamente estáveis.
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
BR0011772A (pt) Conjugado de droga-oligÈmero, composição farmacêutica, método de solubilização de uma droga em uma microemulsão, e, métodos para fornecer um conjugado de droga ativa - hidrófilo e um conjugado de droga ativa - peg a um sìtio de um indivìduo
ATE355829T1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
BR0214431A (pt) Preparação de extrato de gengibre estável, processo para produção da mesma, preparação galênica, e, uso de uma preparação de extrato de gengibre estabilizada e de uma preparação galênica
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
BR9503386A (pt) Formulaçao farmacêutica comprimido dispersivel e processo para a fabricaçao de comprimidos dispersíveis contendo cloridrato de fluoxetina
CY1107672T1 (el) Φαρμακευτικες και/ή κοσμητικες συνθεσεις για τη θεραπεια εντοπισμενου αδιπικου ιστου και κυτταριτιδας
BR0209777A (pt) Formulações lìquidas estáveis
ATE332138T1 (de) Flibanserin zur behandlung extrapyramidaler bewegungsstörungen
DE69809074D1 (de) Herstellung von arzneimitteln
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
BR9809571A (pt) Composição medicinal e processo para produzì-la
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
BR0013106A (pt) Composição farmacêutica flutuante, comprimido, e processo de prepapação de um comprimido.
BR9914441A (pt) Composição de alta pureza compreendendo (7-alfa, 17-alfa) - 17-hidroxi-7-metil-19-nor-17-pregn- 5(10)-en-20-in-3-ona, processo para preparar as composições de alta pureza, e, unidade de dosagem farmacêutica
NO20055016L (no) Farmasoytisk sammensetning som fast doseringsform og fremgangsmate for fremstilling derav
AR018376A1 (es) Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
MXPA02012232A (es) Preparacion antipiretica concentrada de xilitol.
BR0109252A (pt) Composto, processo para produzir um composto, composição farmacêutica, e, uso de um composto ou de uma composição
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa
BR0312003A (pt) Composições farmacêuticas metaestáveis para distribuição transdérmica e seus usos

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/05/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 17.05.2021

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/00, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO